Christopher M Hovens

List of Publications by Citations

118 papers	8,626 citations	38 h-index	92 g-index
124 ext. papers	11,410 ext. citations	8.2 avg, IF	4.89 L-index

#	Paper	IF	Citations
118	The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **2015**, 163, 1011-25	56.2	1713
117	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, **2018**, 173, 400-416.e11	56.2	1072
116	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*, **2018**, 33, 676-689.e3	24.3	377
115	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Reports*, **2018**, 23, 181-193.e7	10.6	366
114	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell*, **2018**, 34, 211-224.e6	24.3	327
113	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Systems*, **2018**, 6, 271-281.e7	10.6	320
112	A B-cell coactivator of octamer-binding transcription factors. *Nature*, **1995**, 373, 360-2	50.4	280
111	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*, **2018**, 33, 706-720.e9	24.3	275
110	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. *Nature Communications*, **2015**, 6, 6605	17.4	245
109	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Reports*, **2018**, 23, 282-296.e4	10.6	188
108	The junction-associated protein AF-6 interacts and clusters with specific Eph receptor tyrosine kinases at specialized sites of cell-cell contact in the brain. *Journal of Cell Biology*, **1999**, 144, 361-71	7.3	175
107	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Systems*, **2018**, 6, 282-300.e2	10.6	159
106	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Reports*, **2018**, 23, 297-312.e12	10.6	147
105	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. *Nature Genetics*, **2000**, 25, 414-8	36.3	144
104	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*, **2018**, 173, 386-399.e12	56.2	133
103	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. *Journal of Clinical Neuroscience*, **2010**, 17, 1025-33	2.2	112
102	Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. *Brain*, **2015**, 138, 1297-313	11.2	105

101	RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 11818-22	11.5	105
100	Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. *BMC Genomics*, **2014**, 15, 51	4.5	96
99	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. *BJU International*, **2011**, 108, E202-10	5.6	83
98	Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. *Journal of Clinical Neuroscience*, **2009**, 16, 1119-30	2.2	80
97	Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. *Brain*, **2016**, 139, 1919-38	11.2	78
96	Mutagenesis and selection of PDZ domains that bind new protein targets. *Nature Biotechnology*, **1999**, 17, 170-5	44.5	78
95	An in vitro assay of beta-galactosidase from yeast. *BioTechniques*, **1996**, 20, 960-2	2.5	78
94	Targeting malignant glioma survival signalling to improve clinical outcomes. *Journal of Clinical Neuroscience*, **2007**, 14, 301-8	2.2	77
93	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 172-180.e3	10.6	66
92	The application of the polymerase chain reaction to cloning members of the protein tyrosine kinase family. *Gene*, **1989**, 85, 67-74	3.8	66
91	A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. *British Journal of Cancer*, **2016**, 114, 454-62	8.7	62
90	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. *BJU International*, **2012**, 109, 660-4	5.6	59
89	Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. *Neurobiology of Disease*, **2012**, 45, 897-901	7.5	58
88	Targeting Stat3 and Smad7 to restore TGF-□cytostatic regulation of tumor cells in vitro and in vivo. *Oncogene*, **2013**, 32, 2433-41	9.2	57
87	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Reports*, **2018**, 23, 213-226.e3	26.6	56
86	The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. *BJU International*, **2012**, 110, 36-42	5.6	48
85	Regulation of glycogen synthase kinase-3 beta (GSK-3)□by the Akt pathway in gliomas. *Journal of Clinical Neuroscience*, **2012**, 19, 1558-63	2.2	48
84	Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes. *Neuropharmacology*, **2016**, 108, 382-93	5.5	46

83	Two versatile eukaryotic vectors permitting epitope tagging, radiolabelling and nuclear localisation of expressed proteins. *Gene*, **1996**, 168, 165-7	3.8	43
82	VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. *Journal of Urology*, **2010**, 184, 1273-8	2.5	40
81	Repair mechanisms help glioblastoma resist treatment. *Journal of Clinical Neuroscience*, **2015**, 22, 14-20	2.2	39
80	Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer. *Clinical Cancer Research*, **2014**, 20, 5547-57	12.9	38
79	Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 591-6	2.8	38
78	Distinct requirements for the Sprouty domain for functional activity of Spred proteins. *Biochemical Journal*, **2005**, 388, 445-54	3.8	38
77	A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 54, 223-32	4.3	38
76	Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. *PLoS ONE*, **2014**, 9, e91729	3.7	37
75	Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities. *Molecular Neurobiology*, **2014**, 49, 1532-9	6.2	37
74	Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. *Journal of Clinical Neuroscience*, **2005**, 12, 1-5	2.2	36
73	Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. *British Journal of Cancer*, **2010**, 103, 462-8	8.7	35
72	Paraneoplastic syndromes in prostate cancer. *Nature Reviews Urology*, **2010**, 7, 681-92	5.5	34
71	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. *Neurotherapeutics* , **2019**, 16, 192-202	6.4	34
70	Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 48.e9-17	2.8	32
69	Error rates in a clinical data repository: lessons from the transition to electronic data transfer--a descriptive study. *BMJ Open*, **2013**, 3,	3	32
68	Glycogen synthase kinase-3 (GSK-3) and its dysregulation in glioblastoma multiforme. *Journal of Clinical Neuroscience*, **2013**, 20, 1185-92	2.2	29
67	Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. *EMBO Reports*, **2020**, 21, e50162	6.5	28
66	How Subclonal Modeling Is Changing the Metastatic Paradigm. *Clinical Cancer Research*, **2017**, 23, 630-635	12.9	26

65	Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. *Pathology*, **2011**, 43, 138-42	1.6	25
64	AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartment. *Journal of Cellular Physiology*, **2007**, 210, 212-23	7	24
63	Androgen synthesis in prostate cancer: do all roads lead to Rome?. *Nature Reviews Urology*, **2017**, 14, 49-58	5.5	23
62	International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. *British Journal of Cancer*, **2012**, 107, 1467-73	8.7	22
61	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. *Clinical Cancer Research*, **2016**, 22, 3132-7	12.9	22
60	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. *BJU International*, **2012**, 110, 821-7	5.6	21
59	Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. *Epilepsia*, **2017**, 58, e136-e141	6.4	21
58	Inferring structural variant cancer cell fraction. *Nature Communications*, **2020**, 11, 730	17.4	19
57	Useful vectors for the two-hybrid system in mammalian cells. *BioTechniques*, **1997**, 23, 396-8, 400, 402	2.5	19
56	Circulating endothelial cells as biomarkers of prostate cancer. *Nature Reviews Urology*, **2008**, 5, 445-54		18
55	The tumour suppressor protein NF2/merlin: the puzzle continues. *Journal of Clinical Neuroscience*, **2001**, 8, 4-7	2.2	18
54	What Is Oligometastatic Prostate Cancer?. *European Urology Focus*, **2019**, 5, 159-161	5.1	17
53	Expression of the adaptor protein Tks5 in human cancer: prognostic potential. *Oncology Reports*, **2014**, 32, 989-1002	3.5	17
52	Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. *Canadian Urological Association Journal*, **2015**, 9, E252-5	1.2	17
51	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. *Experimental Cell Research*, **2019**, 374, 353-364	4.2	16
50	Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy. *British Journal of Cancer*, **2012**, 107, 1564-73	8.7	14
49	Expression of ErbB-1 and 2 in vestibular schwannomas. *Journal of Clinical Neuroscience*, **2007**, 14, 1199-206	2.2	14
48	Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management. *Oncotarget*, **2017**, 8, 71342-71357	3.3	14

47	Comparing nodal versus bony metastatic spread using tumour phylogenies. *Scientific Reports*, **2016**, 6, 33918	4.9	14
46	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. *European Urology*, **2021**, 80, 632-640	10.2	14
45	Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. *Journal of Neuro-Oncology*, **2017**, 131, 321-329	4.8	13
44	Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. *Pathology*, **2014**, 46, 274-82	1.6	13
43	Eve-3: a liver enriched suppressor of Ras/MAPK signaling. *Journal of Hepatology*, **2006**, 44, 758-67	13.4	13
42	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. *Endocrine-Related Cancer*, **2018**, 25, 569-581	5.7	11
41	Routinely reported ŞequivocalSlymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. *BJU International*, **2017**, 119, 567-572	5.6	11
40	Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. *BJU International*, **2013**, 111, 921-7	5.6	11
39	Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. *Endocrine Connections*, **2019**, 8, 547-558	3.5	11
38	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. *Genome Medicine*, **2020**, 12, 72	14.4	11
37	Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2015**, 18, 137-43	6.2	10
36	Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. *Pathology*, **2012**, 44, 204-8	1.6	10
35	Loss of APKC expression independently predicts tumor recurrence in superficial bladder cancers. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 649-55	2.8	9
34	Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. *BJU International*, **2010**, 106, 1081-7	5.6	9
33	An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. *Gene*, **1997**, 197, 337-41	3.8	9
32	Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. *Clinical and Experimental Metastasis*, **2014**, 31, 159-67	4.7	8
31	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. *BJU International*, **2006**, 97, 1149-53	5.6	8
30	Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. *Oncotarget*, **2016**, 7, 31384-92	3.3	8

29	Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. *Journal of Clinical Neuroscience*, **2019**, 63, 213-219	2.2	7
28	Expression of ErbB-1 and ErbB-2 in meningioma. *Journal of Clinical Neuroscience*, **2010**, 17, 1155-8	2.2	6
27	Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination. *Biochemical and Biophysical Research Communications*, **2006**, 351, 1018-23	3.4	5
26	Localization of two mouse genes encoding the protein tyrosine kinase receptor-related protein RYK. *Mammalian Genome*, **1995**, 6, 255-6	3.2	5
25	Rapid screening of highly complex cDNA libraries using the polymerase chain reaction. *Nucleic Acids Research*, **1989**, 17, 4415-6	20.1	5
24	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. *Cancers*, **2020**, 12,	6.6	5
23	Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression. *BJU International*, **2019**, 123, 976-984	5.6	5
22	Obesity suppresses tumor attributable PSA, affecting risk categorization. *Endocrine-Related Cancer*, **2018**, 25, 561-568	5.7	4
21	Bladder cancer biorepositories in the "-omics" era: integrating quality tissue specimens with comprehensive clinical annotation. *Biopreservation and Biobanking*, **2013**, 11, 166-72	2.1	4
20	Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers. *Biomarkers in Medicine*, **2013**, 7, 879-91	2.3	4
19	Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2011**, 29, 237-43	2.8	4
18	Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme. *Journal of Clinical Neuroscience*, **2015**, 22, 1802-8	2.2	3
17	Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer. *Current Cancer Drug Targets*, **2015**, 15, 394-405	2.8	3
16	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. *BMJ Open*, **2020**, 10, e040100	3	3
15	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. *European Journal of Cancer*, **2021**, 148, 440-450	7.5	3
14	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. *Cancer Immunology, Immunotherapy*, **2021**, 70, 1811-1820	7.4	3
13	Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint. *BJU International*, **2008**, 102, 247-52	5.6	2
12	Loss of in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. *JCO Precision Oncology*, **2021**, 5,	3.6	2

11	Androstenedione is the preferred androgen source in hormone refractory prostate cancer--response. *Clinical Cancer Research*, **2014**, 20, 4972-3	12.9	1
10	Reply: on the clinical relevance of circulating endothelial cells and platelets in prostate cancer. *British Journal of Cancer*, **2013**, 108, 1388	8.7	1
9	Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. *BMC Cancer*, **2021**, 21, 846	4.8	1
8	Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study.. *BMJ Neurology Open*, **2021**, 3, e000223	1.5	1
7	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 1167-1180	6.2	0
6	A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia.. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2022**, 8, e12299	6	0
5	Dual translation cassettes which allow prokaryotic and vertebrate protein expression from the same vector. *Technical Tips Online*, **1997**, 2, 91-93		
4	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial.. *BMJ Open*, **2021**, 11, e055019	3	
3	Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation. *MethodsX*, **2019**, 6, 22-34	1.9	
2	Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention **2021**, 319-334		
1	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. *Uro*, **2022**, 2, 74-92		